These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 3592889)

  • 1. Low dose bromocriptine in Parkinson disease. Effects on the clinical picture and hypophyseal hormones.
    Plascencia-Fuentes JM; Cabañas-García A; Corona-Vázquez T; Estañol-Vidal B; López-Mora M; Zárate-Treviño A
    Arch Invest Med (Mex); 1986; 17(2):135-46. PubMed ID: 3592889
    [No Abstract]   [Full Text] [Related]  

  • 2. Bromocriptine in Parkinson disease.
    Lieberman AN; Goldstein M
    Pharmacol Rev; 1985 Jun; 37(2):217-27. PubMed ID: 3901046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bromocriptine: long-term low-dose therapy in Parkinson's disease.
    Teychenne PF; Bergsrud D; Elton RL; Racy A
    Clin Neuropharmacol; 1986; 9(2):138-45. PubMed ID: 3708599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
    Grimes JD; Delgado MR
    Clin Neuropharmacol; 1985; 8(1):73-7. PubMed ID: 3978651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical administration of parlodel in low doses.
    Lipcsey A; Peres A
    Adv Neurol; 1984; 40():557-61. PubMed ID: 6695636
    [No Abstract]   [Full Text] [Related]  

  • 6. [Neuropsychic side effects of bromocriptine in Parkinson's disease].
    Simonetta M; Schmitt L; Montastruc JL; Rascol A
    Rev Neurol (Paris); 1987; 143(8-9):608-11. PubMed ID: 3671965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bromocriptine and lisuride in Parkinson's disease.
    Caraceni T; Giovannini P; Parati E; Scigliano G; Grassi MP; Carella F
    Adv Neurol; 1984; 40():531-5. PubMed ID: 6695632
    [No Abstract]   [Full Text] [Related]  

  • 8. [Improved therapeutic response to L-dopa in Parkinson's disease, when combined with bromocriptine (author's transl)].
    Ulm G
    Nervenarzt; 1981 Feb; 52(2):116-20. PubMed ID: 7219619
    [No Abstract]   [Full Text] [Related]  

  • 9. [Experience with the use of parlodel in the treatment of Parkinson patients].
    Stoliarova LG; Kadykov AS; Shvedkov VV; Pivovarova VM
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1986; 86(2):219-22. PubMed ID: 3705825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease.
    Mizuno Y; Yanagisawa N; Kuno S; Yamamoto M; Hasegawa K; Origasa H; Kowa H;
    Mov Disord; 2003 Oct; 18(10):1149-56. PubMed ID: 14534919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [L-dopa and bromocriptine in Parkinson disease. Early combination therapy has better effect].
    Olsson JE; Duchek M; Ekberg R; Fehling C; Johansson F; Johnels B; Lindvall B; Nordin G; Sidén A; Steg G
    Lakartidningen; 1993 Apr; 90(16):1545-8. PubMed ID: 8483351
    [No Abstract]   [Full Text] [Related]  

  • 12. Sustained bromocriptine therapy in 50 previously untreated patients with Parkinson's disease.
    Stern GM; Lees AJ
    Adv Neurol; 1983; 37():17-21. PubMed ID: 6858771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
    Zimmerman TR; Sage JI; Lang AE; Mark MH
    Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bromocriptine as the 1st treatment of Parkinson's disease. Long term results].
    Rascol A; Montastruc JL; Guiraud-Chaumeil B; Clanet M
    Rev Neurol (Paris); 1982; 138(5):401-8. PubMed ID: 7146724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A comparative study of the effect of bromocriptine and pergolide on Parkinson disease].
    de Yébenes JG; García-Ruiz PJ; Sánchez-Pernaute R
    Rev Neurol; 1997 Sep; 25(145):1343-5. PubMed ID: 9377286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in pituitary hormones serum levels in bromocryptine-treated parkinsonian patients.
    Polleri A; Carolei A; Rolandi E; Masturzo P; Meco G; Agnoli A
    Neuropsychobiology; 1977; 3(1):42-8. PubMed ID: 578293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bromocriptine in Parkinson's disease: report on 106 patients treated for up to 5 years.
    Lieberman AN; Kupersmith M; Neophytides A; Gopinathan G; Casson I; Durso R; Foo SH; Khayali M; Tartaro T; Goldstein M
    Adv Biochem Psychopharmacol; 1980; 23():245-53. PubMed ID: 7395614
    [No Abstract]   [Full Text] [Related]  

  • 18. Bromocriptine and lisuride in Parkinson disease.
    Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Walker R; Hiesiger E
    Ann Neurol; 1983 Jan; 13(1):44-7. PubMed ID: 6830164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Parlodel in early combination with levodopa in the treatment of Parkinson disease. Comparison of 2 dosage forms].
    Goulley F; Wolmark Y; Bourdeix I; Chaumet-Riffaud PD
    Therapie; 1993; 48(3):233-8. PubMed ID: 7908147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure of oral administration of single rising doses of bromocriptine to produce acute anti-Parkinsonian effects.
    Poewe W; Schelosky L; Kleedorfer B
    J Neurol Neurosurg Psychiatry; 1991 Feb; 54(2):186-7. PubMed ID: 2019851
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.